Ro60-0175

Ro60-0175
(IUPAC) ime
	(S)-6-Chloro-5-fluoro-1H-indole-2-propanamine
Klinički podaci
Identifikatori
CAS broj	169675-09-6
ATC kod	?
PubChem	5312145
Hemijski podaci
Formula	C11H12ClFN2
Mol. masa	226.677 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3 ; Key: XJJZQXUGLLXTHO-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Ro60-0175 je lek koji je razvila kompanija Hoffmann–La Roche. On se primenjuje u naučnim istraživanjima.^[3]^[4] Ro60-0175 je potentan i selektivan agonist 5-HT_2B i 5-HT_2C serotoninskih receptorskih tipova, sa dobrom selektivnošću u odnosu na srodni 5-HT_2A tip, i neznatnim afinitetom za druge receptore.^[5]^[6]

Vidi još uredi

Literatura uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Quarta D, Naylor CG, Stolerman IP. The serotonin 2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology (Berlin). 2007 Aug;193(3):391-402. PMID 17473916
↑ Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA. The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology. 2008 May;33(6):1402-12. PMID 17653111
↑ Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. British Journal of Pharmacology. 1999 Sep;128(1):13-20. DOI:10.1038/sj.bjp.0702751 PMID 10498829
↑ Damjanoska KJ, Muma NA, Zhang Y, D'Souza DN, Garcia F, Carrasco GA, Kindel GH, Haskins KA, Shankaran M, Petersen BR, Van De Kar LD. Neuroendocrine evidence that (S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. Journal of Pharmacology and Experimental Therapeutics. 2003 Mar;304(3):1209-16. PMID 12604698

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Quarta D, Naylor CG, Stolerman IP. The serotonin 2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology (Berlin). 2007 Aug;193(3):391-402. PMID 17473916

[4] Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA. The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology. 2008 May;33(6):1402-12. PMID 17653111

[5] Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. British Journal of Pharmacology. 1999 Sep;128(1):13-20. DOI:10.1038/sj.bjp.0702751 PMID 10498829

[6] Damjanoska KJ, Muma NA, Zhang Y, D'Souza DN, Garcia F, Carrasco GA, Kindel GH, Haskins KA, Shankaran M, Petersen BR, Van De Kar LD. Neuroendocrine evidence that (S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. Journal of Pharmacology and Experimental Therapeutics. 2003 Mar;304(3):1209-16. PMID 12604698

[3]

[4]

[5]

[6]

[1]

[2]